-
Innovation Ranking
Innovation Ranking – Clinigen Group Plc
Clinigen Ltd (Clinigen) is a pharmaceutical and services company that provides access to clinical trials, medicines and unlicensed and commercial supplies. The company’s products include dexrazoxane, crisantaspase, amifostine, foscarnet sodium, acetylcysteine, cholecalciferol, folic acid, gabapentin, glycopyrronium bromide, iloprost, and others. It carries out clinical trial services, partnering, IDIS-managed access, clinical supply management, and others. Clinigen's clinical trial services comprise packaging and labeling, direct-to-site delivery, global storage and distribution, ancillary supply sourcing, and controlled drug services. The company serves biotechnology and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LBL-007 in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LBL-007 in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LBL-007 in Hypopharyngeal Cancer Drug Details: LBL-007 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Siremadlin Succinate in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Siremadlin Succinate in Myelofibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Siremadlin Succinate in Myelofibrosis Drug Details: Siremadlin succinate (HDM-201) is under...
-
Company Insights
Innovation and Patenting activity of Clinigen Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Clinigen Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Interferon Gamma-1b in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Gamma-1b in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Gamma-1b in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Interferon Gamma-1B in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Gamma-1B in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Gamma-1B in Metastatic Breast Cancer Drug Details: Human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Interferon Gamma-1b in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Gamma-1b in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Gamma-1b in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewChondrosarcoma – Drugs In Development, 2024
Empower your strategies with our Chondrosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, and changes in urination....
-
Product Insights
NewGastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024
Empower your strategies with our Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2024 report and make more profitable business decisions. Gastrointestinal stromal tumors (GISTs) are tumors that occur in the gastrointestinal tract. GISTs belong to a group of cancers called soft tissue sarcomas. GISTs can be benign or malignant. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can be felt with the hand, nausea and vomiting, vomiting blood or having blood...